Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Adenocarcinoma of Lung 2Mesothelioma, Malignant 1Lymphoma 1Lung Neoplasms 1Colonic Neoplasms 1

Interventions

Carboplatin 17Paclitaxel 16Radiotherapy 10Taxes 9Cisplatin 8Radiation 7Docetaxel 7Gemcitabine 6Gefitinib 6Bevacizumab 6Erlotinib Hydrochloride 5Radiotherapy, Conformal 3Platinum 3Etoposide 31,2-diaminocyclohexaneplatinum II citrate 3methoxyamine 2Vinorelbine 2Tirapazamine 2Pemetrexed 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Disulfides 2Cetuximab 2Bortezomib 2veliparib 1vandetanib 1shark cartilage extract 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Adenocarcinoma of Lung × methoxyamine × Clear all
NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT02535325 2022-06-30

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Completed
17 enrolled
Thoracic

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡